Lakewood-Amedex Inc., a Sarasota, Fla.-based developer of novel anti-infective pharmaceuticals, raised a total of $5.5m is Series C financing.
The company will use the funds to advance is novel broad-spectrum Bisphosphocin™ class of antimicrobials into human clinical trials, increase its business development activities including seeking collaborations and partnerships to advance its orally available ‘gene silencing’ nRNA therapeutics for the treatment of various viral indications, oncology applications, inflammatory conditions and other chronic human diseases.
Led by Steve Parkinson, President and CEO, Lakewood-Amedex is a biopharmaceutical company developing a broad portfolio of innovative novel-approach anti-infective products in the treatment of serious infectious diseases, improving patient outcomes and reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, VRE, NDM-1 and biofilm strains. The company’s products and technology are covered by an extensive patent portfolio consisting of 74 issued and 13 pending patents. Its lead product, Nu-3, a first-in-class antimicrobial, is expected to enter the clinic in the second half of 2014.
Lakewood-Amedex is also developing orally available ‘gene silencing’ nRNA therapeutics for the treatment of various viral indications, oncology applications, inflammatory conditions and other chronic human diseases.
FinSMEs
18/06/2014